Clinicopathologic Features and Outcome of Adenocarcinoma of the Anal Canal: A Population-Based Study.


Journal

International journal of surgical oncology
ISSN: 2090-1410
Titre abrégé: Int J Surg Oncol
Pays: United States
ID NLM: 101566285

Informations de publication

Date de publication:
2020
Historique:
received: 16 03 2020
accepted: 21 04 2020
entrez: 27 5 2020
pubmed: 27 5 2020
medline: 15 12 2020
Statut: epublish

Résumé

Anal canal adenocarcinoma (AA) is an uncommon tumor of the gastrointestinal tract. We seek to provide a detailed description of the incidence, demographics, and outcome of this rare tumor in the United States. The data on anal canal adenocarcinoma from SEER Program, between 1973-2015, were extracted. We analyzed the incidence rates by demographics and tumor characteristics, followed by analysis of its impact on survival. The incidence of AA increased initially by 4.03% yearly from 1973 to 1985 but had a modest decline of 0.32% annually thereafter. The mean age for diagnosis of AA was 68.12 ± 14.02 years. Males outnumbered females by 54.8 to 45.2%. Tumors were mostly localized on presentation (44.4%) and moderately differentiated (41.1%). Age generally correlated with poor overall cancer survival. However, young patients (age <40 years) also showed poor long-term survival. Patients with localized disease and well-differentiated tumors showed better survival outcomes. Surgical intervention improved survival significantly as compared to patients who did not (116.7 months vs 42.7 months, Anal canal adenocarcinoma demonstrated a poor bimodal cancer-free survival in both younger and older patient groups. Surgery significantly improves odds of survival and should be offered to patients amenable to intervention.

Sections du résumé

BACKGROUND BACKGROUND
Anal canal adenocarcinoma (AA) is an uncommon tumor of the gastrointestinal tract. We seek to provide a detailed description of the incidence, demographics, and outcome of this rare tumor in the United States.
METHODS METHODS
The data on anal canal adenocarcinoma from SEER Program, between 1973-2015, were extracted. We analyzed the incidence rates by demographics and tumor characteristics, followed by analysis of its impact on survival.
RESULTS RESULTS
The incidence of AA increased initially by 4.03% yearly from 1973 to 1985 but had a modest decline of 0.32% annually thereafter. The mean age for diagnosis of AA was 68.12 ± 14.02 years. Males outnumbered females by 54.8 to 45.2%. Tumors were mostly localized on presentation (44.4%) and moderately differentiated (41.1%). Age generally correlated with poor overall cancer survival. However, young patients (age <40 years) also showed poor long-term survival. Patients with localized disease and well-differentiated tumors showed better survival outcomes. Surgical intervention improved survival significantly as compared to patients who did not (116.7 months vs 42.7 months,
CONCLUSIONS CONCLUSIONS
Anal canal adenocarcinoma demonstrated a poor bimodal cancer-free survival in both younger and older patient groups. Surgery significantly improves odds of survival and should be offered to patients amenable to intervention.

Identifiants

pubmed: 32455011
doi: 10.1155/2020/5139236
pmc: PMC7243005
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

5139236

Informations de copyright

Copyright © 2020 Shekhar Gogna et al.

Déclaration de conflit d'intérêts

The authors declare that they have no conflicts of interest.

Références

Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1274-83
pubmed: 12873671
Colorectal Dis. 2013 Dec;15(12):1481-8
pubmed: 23809885
Oncologist. 2002;7(3):188-99
pubmed: 12065790
Cancer. 1997 Aug 15;80(4):805-15
pubmed: 9264365
Br J Cancer. 2018 May;118(10):1302-1312
pubmed: 29700411
Ann Surg Oncol. 2009 May;16(5):1310-5
pubmed: 19241106
Dis Colon Rectum. 2019 Dec;62(12):1448-1457
pubmed: 31725581
Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):669-78
pubmed: 12573754
Arch Surg. 1964 Dec;89:989-94
pubmed: 14208473
J Natl Compr Canc Netw. 2019 Oct 1;17(10):1203-1210
pubmed: 31590155
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Dis Colon Rectum. 2003 Oct;46(10):1320-4
pubmed: 14530668
Arch Pathol Lab Med. 2010 Nov;134(11):1601-11
pubmed: 21043813
Dis Colon Rectum. 1988 Apr;31(4):268-72
pubmed: 3359895
Clin Colorectal Cancer. 2016 Mar;15(1):47-53
pubmed: 26362848
Am J Surg. 1995 Feb;169(2):233-7
pubmed: 7840386
Dis Colon Rectum. 1993 Apr;36(4):383-7
pubmed: 8458266
Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1199-205
pubmed: 10613313
Dis Colon Rectum. 2009 Aug;52(8):1375-80
pubmed: 19617747

Auteurs

Shekhar Gogna (S)

Division of Surgical Oncology, Westchester Medical Center, New York Medical College, 100 Woods Road, Taylor Pavilion, Office Suite #353, Valhalla, NY 10595, USA.

Roberto Bergamaschi (R)

Division of Surgical Oncology, Westchester Medical Center, New York Medical College, 100 Woods Road, Taylor Pavilion, Office Suite #353, Valhalla, NY 10595, USA.

Agon Kajmolli (A)

Division of Surgical Oncology, Westchester Medical Center, New York Medical College, 100 Woods Road, Taylor Pavilion, Office Suite #353, Valhalla, NY 10595, USA.

Mahir Gachabayov (M)

Division of Surgical Oncology, Westchester Medical Center, New York Medical College, 100 Woods Road, Taylor Pavilion, Office Suite #353, Valhalla, NY 10595, USA.

Aram Rojas (A)

Division of Surgical Oncology, Westchester Medical Center, New York Medical College, 100 Woods Road, Taylor Pavilion, Office Suite #353, Valhalla, NY 10595, USA.

David Samson (D)

Division of Surgical Oncology, Westchester Medical Center, New York Medical College, 100 Woods Road, Taylor Pavilion, Office Suite #353, Valhalla, NY 10595, USA.

Rifat Latifi (R)

Division of Surgical Oncology, Westchester Medical Center, New York Medical College, 100 Woods Road, Taylor Pavilion, Office Suite #353, Valhalla, NY 10595, USA.

Xiang Da Dong (XD)

Division of Surgical Oncology, Westchester Medical Center, New York Medical College, 100 Woods Road, Taylor Pavilion, Office Suite #353, Valhalla, NY 10595, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH